Lantern Pharma 正在重点介绍其 AI 平台 withZeta.ai，该平台旨在加速罕见癌症药物的发现。据报道，该平台已将开发时间缩短至短短两到三年。该公司计划在投资者简报会上展示这项技术。 AI
影响 加速罕见癌症药物的发现时间，可能降低成本并更快地将治疗方法推向市场。
排序理由 该集群描述了一家公司展示其用于药物发现的 AI 平台，这属于研发里程碑的范畴。
在 Mastodon — sigmoid.social 阅读 →
AI 生成摘要 · Google Gemini · 来自 4 个来源。 我们如何撰写摘要 →
Lantern Pharma to discuss FY2025 results on March 30, highlighting progress on its AI-powered RADR platform for cancer therapy development. # Biotech # AI
Nightfood Holdings acquires BIM-E Autonomous Beverage Robotics Platform, advancing AI-powered automation in hospitality and food service sectors. # Robotics # AI
Lantern Pharma showcases withZeta.ai, its groundbreaking AI platform for rare cancer drug discovery, at April 9 investor briefing. The platform has accelerated development timelines to 2-3 years. # AI # Oncology
Lantern Pharma to showcase withZeta.ai, its multi-agentic AI co-scientist for cancer drug discovery, at April 9 investor briefing. The platform accelerates development timelines and reduces costs dramatically. # AI # Oncology